Skip to main content
TipRanks
Go Ultimate75% OFF

Imunon (CBO0) Stock Price & Analysis

2 Followers

CBO0 Stock Chart & Stats

€0.55€0.00(5.83%)
At close: 5:30 PM GMT+1
€1€1.25€1.5Aug 7Oct 2Oct 27
Day’s Range
EUR 0.55 - EUR 0.71
52-Week Range
EUR 0.52 - EUR 3.54
Previous Close
EUR 0.52
Volume
N/A
Average Volume (3M)
22
Market Cap
EUR 3.70M
Enterprise Value
EUR 10.57M
Total Cash (Recent Filing)
EUR 4.04M
Total Debt (Recent Filing)
EUR 6.94M
Price to Earnings (P/E)
―
Beta
0.15
Next Earnings
Apr 01, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Encouraging IMNN-001 Clinical Signals

Early randomized clinical findings support the biological activity of IMNN-001, while the company also reported favorable safety across studies. Although preliminary and not confirmatory, these signals could strengthen the asset’s development rationale and support continued investment in the pivotal program.

NCI Collaboration Expands Development

The NCI collaboration broadens IMNN-001’s potential clinical application while transferring regulatory and operational responsibility for new studies to a major research partner. This can generate additional evidence and expand the pipeline without diverting as many company resources from OVATION-3.

OVATION-3 Enrollment Productivity

Enrollment above plan provides evidence that the pivotal OVATION-3 trial is progressing with operational productivity at active sites. Sustained execution could improve confidence in the development pathway, support milestone delivery, and help advance IMNN-001 toward a potentially registrational outcome.

Bears Say

Going-concern And Funding Risk

The going-concern disclosure indicates that available liquidity is not sufficient to support the business comfortably through its development plans. This creates persistent financing dependence, increases uncertainty around program continuity, and may constrain strategic flexibility over the next several quarters.

Persistent Losses And Cash Burn

Imunon has no meaningful commercial revenue base and continues to convert operating activity into substantial losses and cash outflows. Until a product generates sales or a program reaches monetization, this economics profile limits self-funding capacity and reinforces the need for external capital.

Trial Completion Depends On Financing And Execution

The pivotal program’s value depends on both securing additional funding and maintaining enrollment performance across a larger site network. Delays or weaker execution could extend the path to interim analysis, increase development spending, and postpone any potential regulatory or commercial benefits.

Imunon News

CBO0 FAQ

What was Imunon’s price range in the past 12 months?
Imunon lowest stock price was €0.52 and its highest was €3.54 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is €3.70M.
When is Imunon’s upcoming earnings report date?
Imunon’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 136 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Nov 12, 2026. The company reported -€0.581 earnings per share for the quarter, missing the consensus estimate of -€0.501 by -€0.08.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon does not currently pay dividends.
What is Imunon’s EPS estimate?
Imunon’s EPS estimate is -0.45.
How many shares outstanding does Imunon have?
Imunon has 6,487,286 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -€0.581 in its last earnings report, missing expectations of -€0.501. Following the earnings report the stock price went up 5.825%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in DE:CBO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology